Personalising glaucoma surgery: The role of MIGS
June 22nd 2021Minimally invasive glaucoma surgery (MIGS) is appealing to glaucoma patients and surgeons; however, it should not be adopted without further high-quality research and careful reporting. Selection of the appropriate treatment for individual patients must be evidence based.
Considering antibiotics use in postoperative endophthalmitis
June 1st 2021Whilst endophthalmitis following cataract surgery can lead to serious vision outcomes, there are ways of minimising the risk of it occurring whilst also being mindful of the need to prescribe antibiotics in a way that does not worsen antimicrobial resistance.
Gene therapy helps patient with retinitis pigmentosa achieve partial vision
May 26th 2021An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.
Johnson & Johnson Vision, Alcon engaged in intellectual property dispute
May 18th 2021After a US District judge rules against request for preliminary injunction, Johnson & Johnson Vision moves forward with litigation in several countries, including the United States, to resolve intellectual property disputes against Alcon.
Treatment with voretigene neparvovec-rzyl results in foveal morphologic changes in LCA
May 10th 2021In a presentation at ARVO, Friederike Kortuem, MD, MSc, explains that treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.
Diabetes and DR: Making progress in the global epidemic
May 5th 2021During a presentation at the ARVO virtual meeting, Lloyd Paul Aiello, MD, PhD, explains that a key hurdle for diabetic retinopathy is the lack of patient awareness, which is a substantial contributor to non-adherence to eye care guidelines and poor outcomes.
Initial data from AGTC-501 subretinal gene therapy for X-linked RP demonstrates safety, efficacy
May 5th 2021During an ARVO presentation, Paul Yang, MD, PhD, explained that in a clinical trial, investigators used an adeno-associated viral vector to deliver a normal functioning copy of the RPGR gene via subretinal injection.